Dr. Thomas E. Hutson on results of phase 3 CLEAR trial of pembrolizumab/lenvatinib in RCC

The immunotherapy/TKI combination significantly improved overall survival versus sunitinib.

Thomas E. Hutson, DO, PharmD, Texas Oncology‐Baylor Charles A. Sammons Cancer Center, discusses findings from the phase 3 CLEAR trial, in which frontline therapy with pembrolizumab (Keytruda) plus lenvatinib (Lenvima) reduced the risk of death by 34% versus sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC). The combination also improved progression-free survival (PFS) and response compared with sunitinib. In the trial, it was also demonstrated that combining lenvatinib and everolimus improved PFS and objective response rate but not OS versus sunitinib in this setting (J Clin Oncol. 2021; 39[suppl6]:269. doi: 10.1200/JCO.2021.39.6_suppl.269).